Effectiveness and safety of anakinra for management of refractory pericarditis

Sonia Jain, Charat Thongprayoon, Raul Emilio Espinosa, Sharonne N. Hayes, Kyle W. Klarich, Leslie T Jr. Cooper, Kevin G. Moder, Nandan S. Anavekar, Jae Kuen Oh, Eric Lawrence Matteson

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Recurrent pericarditis is a debilitating condition that can be recalcitrant to conventional therapy with nonsteroidal anti-inflammatory agents, colchicine, and glucocorticoids. The aim of this study was to evaluate the therapeutic role of the recombinant interleukin-1 receptor antagonist anakinra in a series of adult patients with recurrent pericarditis refractory to conventional therapy. We retrospectively reviewed the medical records of 13 consecutive patients with treatment-refractory recurrent pericarditis who received anakinra for management of their disease. None of the patients had an identified systemic inflammatory rheumatic disease. The primary end points were symptom resolution and glucocorticoid discontinuation. Thirteen patients (10 women) treated with anakinra were followed for a median (range) of 16.8 months (1.3 to 24). All patients had chest pain. Total duration of symptoms before initiation of anakinra was 3 years (1.1 to 6.0). Pericardial thickening was detected by echocardiography in 9 patients (69%). All 13 patients (100%) experienced at least a partial and, most, a complete resolution of symptoms. Response to therapy was rapid, within 2 to 5 days. At last follow-up, 11 patients (84%) had successfully discontinued concomitant nonsteroidal anti-inflammatory agent, colchicine, and glucocorticoid therapy; 11 patients remained on anakinra at the end of the follow-up period. The only side effect was transient injection site reaction in 4 patients (31%). In conclusion, anakinra may be an effective alternative agent for the management of glucocorticoid-dependent recurrent pericarditis. Side effects were minor. A formal clinical trial to evaluate the usefulness of this agent should be considered.

Original languageEnglish (US)
Pages (from-to)1277-1279
Number of pages3
JournalAmerican Journal of Cardiology
Volume116
Issue number8
DOIs
StatePublished - Oct 15 2015

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Safety Management
Pericarditis
Glucocorticoids
Colchicine
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Interleukin-1 Receptors
Disease Management
Rheumatic Diseases
Chest Pain
Medical Records
Echocardiography
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effectiveness and safety of anakinra for management of refractory pericarditis. / Jain, Sonia; Thongprayoon, Charat; Espinosa, Raul Emilio; Hayes, Sharonne N.; Klarich, Kyle W.; Cooper, Leslie T Jr.; Moder, Kevin G.; Anavekar, Nandan S.; Oh, Jae Kuen; Matteson, Eric Lawrence.

In: American Journal of Cardiology, Vol. 116, No. 8, 15.10.2015, p. 1277-1279.

Research output: Contribution to journalArticle

Jain, Sonia ; Thongprayoon, Charat ; Espinosa, Raul Emilio ; Hayes, Sharonne N. ; Klarich, Kyle W. ; Cooper, Leslie T Jr. ; Moder, Kevin G. ; Anavekar, Nandan S. ; Oh, Jae Kuen ; Matteson, Eric Lawrence. / Effectiveness and safety of anakinra for management of refractory pericarditis. In: American Journal of Cardiology. 2015 ; Vol. 116, No. 8. pp. 1277-1279.
@article{a3428cd0cde44ab49a05e8de84b1a350,
title = "Effectiveness and safety of anakinra for management of refractory pericarditis",
abstract = "Recurrent pericarditis is a debilitating condition that can be recalcitrant to conventional therapy with nonsteroidal anti-inflammatory agents, colchicine, and glucocorticoids. The aim of this study was to evaluate the therapeutic role of the recombinant interleukin-1 receptor antagonist anakinra in a series of adult patients with recurrent pericarditis refractory to conventional therapy. We retrospectively reviewed the medical records of 13 consecutive patients with treatment-refractory recurrent pericarditis who received anakinra for management of their disease. None of the patients had an identified systemic inflammatory rheumatic disease. The primary end points were symptom resolution and glucocorticoid discontinuation. Thirteen patients (10 women) treated with anakinra were followed for a median (range) of 16.8 months (1.3 to 24). All patients had chest pain. Total duration of symptoms before initiation of anakinra was 3 years (1.1 to 6.0). Pericardial thickening was detected by echocardiography in 9 patients (69{\%}). All 13 patients (100{\%}) experienced at least a partial and, most, a complete resolution of symptoms. Response to therapy was rapid, within 2 to 5 days. At last follow-up, 11 patients (84{\%}) had successfully discontinued concomitant nonsteroidal anti-inflammatory agent, colchicine, and glucocorticoid therapy; 11 patients remained on anakinra at the end of the follow-up period. The only side effect was transient injection site reaction in 4 patients (31{\%}). In conclusion, anakinra may be an effective alternative agent for the management of glucocorticoid-dependent recurrent pericarditis. Side effects were minor. A formal clinical trial to evaluate the usefulness of this agent should be considered.",
author = "Sonia Jain and Charat Thongprayoon and Espinosa, {Raul Emilio} and Hayes, {Sharonne N.} and Klarich, {Kyle W.} and Cooper, {Leslie T Jr.} and Moder, {Kevin G.} and Anavekar, {Nandan S.} and Oh, {Jae Kuen} and Matteson, {Eric Lawrence}",
year = "2015",
month = "10",
day = "15",
doi = "10.1016/j.amjcard.2015.07.047",
language = "English (US)",
volume = "116",
pages = "1277--1279",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Effectiveness and safety of anakinra for management of refractory pericarditis

AU - Jain, Sonia

AU - Thongprayoon, Charat

AU - Espinosa, Raul Emilio

AU - Hayes, Sharonne N.

AU - Klarich, Kyle W.

AU - Cooper, Leslie T Jr.

AU - Moder, Kevin G.

AU - Anavekar, Nandan S.

AU - Oh, Jae Kuen

AU - Matteson, Eric Lawrence

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Recurrent pericarditis is a debilitating condition that can be recalcitrant to conventional therapy with nonsteroidal anti-inflammatory agents, colchicine, and glucocorticoids. The aim of this study was to evaluate the therapeutic role of the recombinant interleukin-1 receptor antagonist anakinra in a series of adult patients with recurrent pericarditis refractory to conventional therapy. We retrospectively reviewed the medical records of 13 consecutive patients with treatment-refractory recurrent pericarditis who received anakinra for management of their disease. None of the patients had an identified systemic inflammatory rheumatic disease. The primary end points were symptom resolution and glucocorticoid discontinuation. Thirteen patients (10 women) treated with anakinra were followed for a median (range) of 16.8 months (1.3 to 24). All patients had chest pain. Total duration of symptoms before initiation of anakinra was 3 years (1.1 to 6.0). Pericardial thickening was detected by echocardiography in 9 patients (69%). All 13 patients (100%) experienced at least a partial and, most, a complete resolution of symptoms. Response to therapy was rapid, within 2 to 5 days. At last follow-up, 11 patients (84%) had successfully discontinued concomitant nonsteroidal anti-inflammatory agent, colchicine, and glucocorticoid therapy; 11 patients remained on anakinra at the end of the follow-up period. The only side effect was transient injection site reaction in 4 patients (31%). In conclusion, anakinra may be an effective alternative agent for the management of glucocorticoid-dependent recurrent pericarditis. Side effects were minor. A formal clinical trial to evaluate the usefulness of this agent should be considered.

AB - Recurrent pericarditis is a debilitating condition that can be recalcitrant to conventional therapy with nonsteroidal anti-inflammatory agents, colchicine, and glucocorticoids. The aim of this study was to evaluate the therapeutic role of the recombinant interleukin-1 receptor antagonist anakinra in a series of adult patients with recurrent pericarditis refractory to conventional therapy. We retrospectively reviewed the medical records of 13 consecutive patients with treatment-refractory recurrent pericarditis who received anakinra for management of their disease. None of the patients had an identified systemic inflammatory rheumatic disease. The primary end points were symptom resolution and glucocorticoid discontinuation. Thirteen patients (10 women) treated with anakinra were followed for a median (range) of 16.8 months (1.3 to 24). All patients had chest pain. Total duration of symptoms before initiation of anakinra was 3 years (1.1 to 6.0). Pericardial thickening was detected by echocardiography in 9 patients (69%). All 13 patients (100%) experienced at least a partial and, most, a complete resolution of symptoms. Response to therapy was rapid, within 2 to 5 days. At last follow-up, 11 patients (84%) had successfully discontinued concomitant nonsteroidal anti-inflammatory agent, colchicine, and glucocorticoid therapy; 11 patients remained on anakinra at the end of the follow-up period. The only side effect was transient injection site reaction in 4 patients (31%). In conclusion, anakinra may be an effective alternative agent for the management of glucocorticoid-dependent recurrent pericarditis. Side effects were minor. A formal clinical trial to evaluate the usefulness of this agent should be considered.

UR - http://www.scopus.com/inward/record.url?scp=84942552353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942552353&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.07.047

DO - 10.1016/j.amjcard.2015.07.047

M3 - Article

C2 - 26279106

AN - SCOPUS:84942552353

VL - 116

SP - 1277

EP - 1279

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -